Secondary and therapy-related acute myeloid leukaemia

What changed: Secondary and therapy-related acute myeloid leukaemia

Cancer page →

Every dated change on the records linked to Secondary and therapy-related acute myeloid leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval2Trial result2Milestone4This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordSecondary and therapy-related acute myeloid leukaemia
Facts on this page last checked
When this page itself was last checked or edited.

2023 · 1

2023MilestoneMagrolimab
Magrolimab with azacitidine fails in TP53-mutated AML
A milestone in how this cancer is treated.

2020 · 1

2020Trial resultVIALE-A
VIALE-A reported
OS 14.

2018 · 1

2018Trial resultCPX-351 Study 301
CPX-351 Study 301 reported
OS 9.

2017 · 2

2016 · 1

2016MilestoneSecondary and therapy-related acute myeloid leukaemia
WHO defines AML with myelodysplasia-related changes as its own group
A milestone in how this cancer is treated.

2012 · 1

2012ApprovalDecitabine
Decitabine approved in EU
Newly diagnosed de novo or secondary AML in adults 65 and over not candidates for standard induction

1970 · 1

1970MilestoneSecondary malignancy (therapy-related cancer)
Therapy-related leukaemia recognised after alkylating agents for Hodgkin lymphoma
A milestone in how this cancer is treated.